Eli Lilly Abandons Weight Loss Pill Trials!

This episode of On The Pen: The Weekly Dose Podcast breaks down four major stories in obesity medicine: the FDA’s approval of Teva’s so-called “generic” Saxenda at a sky-high price, Wegovy’s accelerated approval in MASH, Novo Nordisk’s headline-grabbing but shaky 57% cardiovascular benefit claim, and Eli Lilly’s decision to scrap its oral GLP-1 naperiglipron. We cut through the spin to ask what these developments really mean for patients fighting for access and better treatment options.

Visit All Our Links
https://linktr.ee/manonthemounjaro

GLP-1 Heart Study
https://onthepen.substack.com/p/new-study-glp-1-drugs-protect-the